Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $29.6 million.

  • Keros Therapeutics' Operating Expenses fell 4979.08% to $29.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.1 million, marking a year-over-year decrease of 75.82%. This contributed to the annual value of $214.4 million for FY2024, which is 2603.94% up from last year.
  • Per Keros Therapeutics' latest filing, its Operating Expenses stood at $29.6 million for Q3 2025, which was down 4979.08% from $58.0 million recorded in Q2 2025.
  • Keros Therapeutics' 5-year Operating Expenses high stood at $59.2 million for Q1 2025, and its period low was $15.6 million during Q2 2021.
  • For the 5-year period, Keros Therapeutics' Operating Expenses averaged around $38.0 million, with its median value being $38.9 million (2023).
  • As far as peak fluctuations go, Keros Therapeutics' Operating Expenses surged by 9645.8% in 2022, and later crashed by 4979.08% in 2025.
  • Over the past 5 years, Keros Therapeutics' Operating Expenses (Quarter) stood at $24.9 million in 2021, then rose by 28.53% to $32.0 million in 2022, then surged by 45.8% to $46.6 million in 2023, then increased by 20.81% to $56.3 million in 2024, then crashed by 47.34% to $29.6 million in 2025.
  • Its Operating Expenses was $29.6 million in Q3 2025, compared to $58.0 million in Q2 2025 and $59.2 million in Q1 2025.